Pediatric Immunology

Standard Treatments and Long-Term Management

At a Glance

For children with ARHGEF1 deficiency, long-term care centers on immunoglobulin replacement with IVIG or SCIG, techniques to clear mucus from the airways, and careful vaccine planning. These measures reduce serious infections and protect lung health but do not correct the genetic cause.

While the genetic cause of ARHGEF1 deficiency is rare, the treatment strategy is built on decades of success in managing other antibody deficiencies. The primary goal is to provide your child’s body with the tools it cannot make itself: protective antibodies to stop the cycle of infection and protect the lungs ^[1]^[2].

Immunoglobulin Replacement Therapy (IRT)

The cornerstone of treatment for clinically significant antibody deficiency is Immunoglobulin Replacement Therapy. This involves taking antibodies (IgG) collected from thousands of healthy donors and giving them to your child ^[2]^[3]. This doesn’t “cure” the genetic glitch, but it “replaces” the missing defense force so your child can fight off common germs ^[4]^[1]. Keep in mind that while IRT significantly reduces serious infections, it does not prevent every viral illness and cannot reverse existing bronchiectasis.

There are two main ways to receive this treatment, and the choice, dose, and frequency are highly individualized based on your child’s infection burden, weight, and clinical response:

Intravenous Immunoglobulin (IVIG): This is usually given in a clinic or hospital every 3 to 4 weeks through a vein ^[5]. It provides a large “boost” of antibodies all at once.
Subcutaneous Immunoglobulin (SCIG): This is given more frequently (often once a week) using small needles placed just under the skin ^[6]. Many parents learn to do this at home. SCIG keeps antibody levels more stable throughout the month and tends to have fewer whole-body side effects ^[7]^[8].

Common and Severe Side Effects: With IVIG, children may experience “flu-like” symptoms like headache, fever, or chills shortly after the infusion ^[5]. With SCIG, the most common issue is temporary redness, swelling, or itching at the injection site ^[6]. However, severe infusion reactions—such as severe headache, chest pain, difficulty breathing, rash, or high fever—require immediate attention. Work with your team to establish an infusion-reaction plan outlining when to stop the infusion, when to call the clinic, and when to seek emergency care.

Managing Bronchiectasis and Lung Health

If your child has developed bronchiectasis (scarring of the airways), replacing antibodies is only half of the plan. The other half is keeping the lungs clear ^[9]^[10].

Airway Clearance (Chest Physiotherapy): This involves techniques to help “shake loose” trapped mucus so it can be coughed out ^[11]. This may include manual clapping on the chest, using a vibrating vest, or special breathing exercises ^[12].
Prophylactic Antibiotics: In some cases where infections persist, a doctor may consider long-term, low-dose antibiotics (such as a macrolide like azithromycin) to prevent new infections and reduce inflammation. This is not a universal treatment. It requires careful specialist assessment due to risks of antimicrobial resistance, drug interactions, heart rhythm (QT prolongation) risks, and liver or hearing effects. Never start or stop this therapy without your care team’s monitoring ^[13]^[14].
Vaccination Precautions: General advice to “stay up to date” on vaccines does not apply here. While some inactivated vaccines (like pneumococcal vaccines) are recommended, live-virus vaccines may be unsafe or contraindicated for your child. Additionally, donor immunoglobulin can interfere with how some vaccines work. Always review every vaccine with your immunologist before administration ^[14]^[15].

The Future of Treatment

In laboratory studies, scientists have found that if they manually “turn on” the RhoA protein or provide a working copy of the ARHGEF1 gene to cells in a dish, the cells begin to behave normally again ^[1]. While this is not yet a treatment available in a pharmacy (and there are no approved targeted therapies today), it provides a “proof of concept” for future therapies that might one day target the root cause of the condition rather than just replacing the missing antibodies ^[16]^[17]. For now, the standard of care—immunoglobulin and lung protection—remains the most effective way to keep your child healthy ^[18].

Common questions in this guide

What is the main treatment for ARHGEF1 deficiency?

The main treatment is immunoglobulin replacement therapy, which supplies IgG antibodies collected from healthy donors. It can reduce serious infections but does not correct the genetic cause or reverse existing bronchiectasis.

Should my child receive IVIG or SCIG?

Both are forms of immunoglobulin replacement. IVIG is usually given through a vein every three to four weeks in a clinic or hospital, while SCIG is often given weekly under the skin and may be administered at home. The immunology team chooses the approach based on infection burden, weight, and clinical response.

What side effects should I watch for during immunoglobulin treatment?

IVIG may cause headache, fever, or chills, while SCIG commonly causes temporary redness, swelling, or itching where it is given. Severe headache, chest pain, difficulty breathing, rash, or high fever needs immediate attention. Follow the infusion-reaction plan from your care team about when to stop treatment, call the clinic, or seek emergency care.

How can bronchiectasis be managed in a child with ARHGEF1 deficiency?

Airway-clearance methods such as chest clapping, a vibrating vest, or breathing exercises can help remove trapped mucus. Children with persistent infections may sometimes be considered for low-dose preventive antibiotics, but this requires specialist monitoring. Immunoglobulin replacement reduces serious infections but cannot reverse existing bronchiectasis.

Are vaccines safe for children with ARHGEF1 deficiency?

Some inactivated vaccines, including pneumococcal vaccines, may be recommended, but live-virus vaccines may be unsafe or contraindicated. Donor immunoglobulin can also interfere with how some vaccines work. Review every vaccine with your child's immunologist before it is given.

Are gene-targeted treatments available for ARHGEF1 deficiency?

There are no approved targeted therapies for ARHGEF1 deficiency at present. Laboratory studies suggest that restoring ARHGEF1 function or activating RhoA may help cells behave normally, but these approaches are experimental; current care relies on immunoglobulin replacement and lung protection.

Get notified when new evidence is published on Childhood-onset common variable immunodeficiency due to ARHGEF1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Loss of ARHGEF1 causes a human primary antibody deficiency.
Bouafia A, Lofek S, Bruneau J, et al.
The Journal of clinical investigation 2019; (129(3)):1047-1060.
PMID: 30521495
2
An Expert Opinion/Approach: Clinical Presentations, Diagnostic Considerations, and Therapeutic Options for Gastrointestinal Manifestations of Common Variable Immune Deficiency.
Hashash JG, Squire J, Francis FF, et al.
The American journal of gastroenterology 2022; (117(11)):1743-1752 doi:10.14309/ajg.0000000000002027.
PMID: 36148549
3
When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
Jolles S, Chapel H, Litzman J
Clinical and experimental immunology 2017; (188(3)):333-341 doi:10.1111/cei.12915.
PMID: 28000208
4
Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.
Pecoraro A, Crescenzi L, Granata F, et al.
International immunopharmacology 2017; (52()):136-142 doi:10.1016/j.intimp.2017.09.005.
PMID: 28898770
5
Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy and asthma proceedings 2016; (37(6)):426-431 doi:10.2500/aap.2016.37.3987.
PMID: 27931296
6
Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency.
Wasserman RL
Immunology and allergy clinics of North America 2019; (39(1)):95-111 doi:10.1016/j.iac.2018.08.001.
PMID: 30466775
7
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C, Iacopelli J, Pecoraro A, et al.
International journal of immunopathology and pharmacology 2017; (30(1)):73-82 doi:10.1177/0394632016681577.
PMID: 27927705
8
Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies.
Shrestha P, Karmacharya P, Wang Z, et al.
The World Allergy Organization journal 2019; (12(10)):100068 doi:10.1016/j.waojou.2019.100068.
PMID: 31641401
9
Airway-Clearance Techniques in Children and Adolescents with Chronic Suppurative Lung Disease and Bronchiectasis.
Lee AL, Button BM, Tannenbaum EL
Frontiers in pediatrics 2017; (5()):2 doi:10.3389/fped.2017.00002.
PMID: 28168184
10
Monitoring disease progression in childhood bronchiectasis.
Ramsey KA, Schultz A
Frontiers in pediatrics 2022; (10()):1010016 doi:10.3389/fped.2022.1010016.
PMID: 36186641
11
Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence?
Snijders D, Fernandez Dominguez B, Calgaro S, et al.
International journal of immunopathology and pharmacology 2015; (28(2)):150-9 doi:10.1177/0394632015584724.
PMID: 26078380
12
Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: A randomized control trial.
Anuradha KWDA, Gunathilaka PKG, Wickramasinghe VP
Pediatric pulmonology 2021; (56(2)):509-515 doi:10.1002/ppul.25206.
PMID: 33295693
13
Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis.
Lee E, Sol IS, Kim JD, et al.
Scientific reports 2021; (11(1)):24287 doi:10.1038/s41598-021-03778-8.
PMID: 34930997
14
Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review.
Faverio P, Franco G, Landoni V, et al.
Journal of clinical medicine 2024; (13(16)) doi:10.3390/jcm13164757.
PMID: 39200899
15
Bronchiectasis With Inborn Errors of Immunity: Zooming in on Predominantly Antibody Deficiencies.
Galant-Swafford J, Lommatzsch S, Alam R, Janoff EN
The journal of allergy and clinical immunology. In practice 2026; (14(9)):2028-2037 doi:10.1016/j.jaip.2026.06.045.
PMID: 42447990
16
The autoimmune conundrum in common variable immunodeficiency disorders.
van de Ven AA, Warnatz K
Current opinion in allergy and clinical immunology 2015; (15(6)):514-24 doi:10.1097/ACI.0000000000000218.
PMID: 26485099
17
An updated review on activated PI3 kinase delta syndrome (APDS).
Singh A, Joshi V, Jindal AK, et al.
Genes & diseases 2020; (7(1)):67-74 doi:10.1016/j.gendis.2019.09.015.
PMID: 32181277
18
Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients.
Wolf HM, Thon V, Litzman J, Eibl MM
Frontiers in immunology 2015; (6()):32 doi:10.3389/fimmu.2015.00032.
PMID: 25699049

This page is for informational purposes only and does not constitute medical advice. Your child's immunologist and care team should tailor immunoglobulin, vaccine, lung-care, and antibiotic decisions to your child.